A novel drug to prevent diabetes onset with potential to reverse the symptoms of metabolic disorder is being developed by a team of scientists. The team has developed soluble epoxide hydrolase or sEH inhibitor that prevent diabetes onset and reverse diabetes symptoms in obese mice. The study was published in the Proceedings of the National Academy of Sciences.
The ongoing study is being conducted by Dr. Bruce Hammock at the University of California and Dr. Joan Claria at the University of Barlecona. In experimental studies, the enzyme inhibitor molecule significantly reduced inflammatory pain, inflammation and neuropathic pain symptoms.
According to Dr. Bruce, the study demonstrated the efficacy of new drug molecule in reduction of diabetes symptoms in experimental animals. The drug acts by stabilizing metabolites of omega-3 fatty acids, DHA and contribute to therapeutic effects, particularly in individuals with higher circulatory levels of omega-3 fatty acids.
Previous studies conducted by the team have shown that the drug reversed or reduced diabetes-associated complications such diabetic pain, hypertension, renal failures and arteriosclerosis.
In future medicine, sEH inhibitor is a promising therapeutic strategy to prevent obesity-related co-morbidities including diabetes, the author noted.
Find us on facebook